

# Atul Humar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3234220/publications.pdf>

Version: 2024-02-01

43  
papers

3,663  
citations

279798

23  
h-index

265206

42  
g-index

43  
all docs

43  
docs citations

43  
times ranked

5723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 226-233.	3.9	46
2	Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. <i>American Journal of Transplantation</i> , 2022, 22, 2089-2093.	4.7	61
3	Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave. <i>Clinical Infectious Diseases</i> , 2022, 75, 2193-2200.	5.8	40
4	Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study. <i>Transplantation</i> , 2022, 106, 1622-1628.	1.0	15
5	Tacrolimus Impairs Kupffer Cell Capacity to Control Bacteremia: Why Transplant Recipients Are Susceptible to Infection. <i>Hepatology</i> , 2021, 73, 1967-1984.	7.3	11
6	The economic impact of increased length of stay associated with surgical site infections in liver transplantation on Canadian healthcare costs. <i>Clinical Transplantation</i> , 2021, 35, e14155.	1.6	3
7	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 498-510.	10.7	180
8	Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia. <i>American Journal of Transplantation</i> , 2021, 21, 3829-3830.	4.7	5
9	Management of refractory and resistant CMV: A step forward but more work needed. <i>Transplant Infectious Disease</i> , 2021, 23, e13704.	1.7	0
10	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	4.7	120
11	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 1244-1246.	27.0	456
12	Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study. <i>Transplant Infectious Disease</i> , 2021, 23, e13743.	1.7	5
13	Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13207.	1.7	9
14	Initial lung transplantation experience with uncontrolled donation after cardiac death in North America. <i>American Journal of Transplantation</i> , 2020, 20, 1574-1581.	4.7	42
15	Long-lasting cluster of nosocomial pneumonia with a single <i>Pneumocystis jirovecii</i> genotype involving different organ allograft recipients. <i>Clinical Transplantation</i> , 2020, 34, e14108.	1.6	3
16	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	8.1	76
17	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma type post-transplant lymphoproliferative disorder. <i>British Journal of Haematology</i> , 2020, 189, 97-105.	2.5	12
18	Liver Transplantation for Acute Liver Failure Due to Dengue Fever. <i>Hepatology</i> , 2019, 70, 1863-1865.	7.3	12

#	ARTICLE	IF	CITATIONS
19	Chronic <i>Candida dubliniensis</i> meningitis in a lung transplant recipient. <i>Medical Mycology Case Reports</i> , 2019, 24, 41-43.	1.3	6
20	Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2495-2504.	4.7	19
21	Cytokine profile in lung transplant recipients with <i>Aspergillus</i> spp colonization. <i>Transplant Infectious Disease</i> , 2019, 21, e13060.	1.7	3
22	The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. <i>Transplantation</i> , 2018, 102, 900-931.	1.0	784
23	Echinocandin use in lung transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13437.	1.6	4
24	Effect of organ donation after circulatory determination of death on number of organ transplants from donors with neurologic determination of death. <i>Cmaj</i> , 2017, 189, E1206-E1211.	2.0	22
25	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. <i>PLoS Pathogens</i> , 2017, 13, e1006299.	4.7	12
26	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. <i>Liver Transplantation</i> , 2016, 22, 324-332.	2.4	25
27	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. <i>Clinical Infectious Diseases</i> , 2016, 62, 1154-1160.	5.8	24
28	Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0123171.	2.5	21
29	Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. <i>Clinical and Translational Immunology</i> , 2014, 3, e12.	3.8	107
30	IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004556.	4.7	108
31	Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2014, 210, 717-727.	4.0	68
32	Levofloxacin for BK Virus Prophylaxis Following Kidney Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2106.	7.4	102
33	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 96, 333-360.	1.0	651
34	Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine Profiling. <i>Transplantation</i> , 2013, 95, 448-455.	1.0	38
35	Reactivation of Viruses in Solid Organ Transplant Patients Receiving Cytomegalovirus Prophylaxis. <i>Transplantation</i> , 2006, 82, S9-S14.	1.0	51
36	A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder. <i>Transplantation</i> , 2006, 81, 856-861.	1.0	86

#	ARTICLE	IF	CITATIONS
37	Clinical Utility of Cytomegalovirus Viral Load Testing for Predicting CMV Disease in D+/R- Solid Organ Transplant Recipients. American Journal of Transplantation, 2004, 4, 644-649.	4.7	93
38	Cytomegalovirus (CMV) Glycoprotein B Genotypes and Response to Antiviral Therapy, in Solidâ€œOrganâ€ Transplant Recipients with CMV Disease. Journal of Infectious Diseases, 2003, 188, 581-584.	4.0	71
39	Interactions Between Cytomegalovirus, Human Herpesvirus-6, and the Recurrence of Hepatitis C After Liver Transplantation. American Journal of Transplantation, 2002, 2, 461-466.	4.7	89
40	Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation, 2002, 73, 599-604.	1.0	104
41	Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. Journal of Medical Microbiology, 2001, 50, 535-546.	1.8	58
42	A Cross-Canada Survey of Cytomegalovirus Prevention and Treatment Practices in Bone Marrow Transplant Recipients. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 410-414.	0.3	1
43	Disseminated Bartonella infection with granulomatous hepatitis in a liver transplant recipient. Liver Transplantation, 1999, 5, 249-251.	1.8	20